hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NVO) shares crashed on Friday, while its rival Eli Lilly (NYSE:LLY) surged after the Danish drugmaker posted late-stage trial data for its next-gen weight loss therapy, CagriSema.
The company said the once-weekly injectable caused up to ~23% of weight loss